Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

Hurwitz, Herbert I.; Douglas, P. S.; Middleton, JohnD.; Sledge, G. W.; Johnson, D. H.; Reardon, David A.; Chen, D.; Rosen, Oliver

doi:10.1200/jco.2010.28.15_suppl.3039

Cited by 39 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, hypertension -a commonly seen side effect of anti-angiogenic treatment -has been proposed to be predictive of patient response and outcome. However, in the largest retrospective analysis of clinical trials, hypertension was not predictive of PFS and OS but in one study (Hurwitz et al, 2010). A clinically implemented predictive biomarker exists preceding treatment with the inhibitor of endothelial growth factor (EGFR)-inhibitor cetuximab, which is initiated upon detection of the wild type KRAS allele (Tol et al, 2009).…”

Section: From Bench To Clinic and Vice Versa -Unanticipated Lessons Fmentioning

confidence: 95%

Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies

Oliveira

Hamm²,

Mazzone³

2011

Molecular Aspects of Medicine

View full text Add to dashboard Cite

Section: From Bench To Clinic and Vice Versa -Unanticipated Lessons Fmentioning

confidence: 95%

Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies

Oliveira

Hamm²,

Mazzone³

2011

Molecular Aspects of Medicine

View full text Add to dashboard Cite

“…The exact mechanism is still not fully understood, however it is believed that VEGF inhibition reduces the synthesis of nitric oxide, increasing vasoconstriction and consequently increasing blood pressure [125]. Hypertension might therefore be a useful surrogate marker of the anti-angiogenic activity of bevacizumab and other VEGF inhibitors, although different studies showed conflicting results about its correlation to the patient's outcome [126][127][128].…”

Section: Predictive Markers and New Drugsmentioning

confidence: 98%

Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors

Bagnasco

Piras²,

Parodi

et al. 2012

CCDT

View full text Add to dashboard Cite

Angiogenesis is a key factor in the carcinogenesis process. In oncological practice, angiogenesis inhibition, mainly through the blockade of the VEGF family and its receptors, has been robustly demonstrated to produce clinical benefits and, in specific disease subsets such as colorectal cancer, to extend the overall survival of treated patients. VEGF is a multifunctional growth factor that mediates its functions through cognate receptors on endothelial cells and it has been discovered for its capability to induce macromolecule hyperpermeability in veins and venules. Several approaches have been taken to target angiogenesis in cancer: drugs that target one or more soluble ligands of the VEGF family, drugs that selectively inhibit one or more receptors of the VEGF receptor family, and drugs that inhibit VEGF receptor(s) among other, non VEGF-related targets. At present, two compounds have shown significant clinical activity, bevacizumab, Avastin® and aflibercept, Zaltrap®, and only one of these (bevacizumab) has so far been registered for use in clinical practice. In the present review, we explore and summarize the main features of the angiogenetic process, concerning in particular a common and potentially lethal disease as colorectal cancer. We overview the molecular pathways that characterize angiogenesis, focusing on VEGF family, the current applications and limitations of its blockade in oncology, and the hypothetical future perspectives of anti-angiogenic therapy.

show abstract

“…The role of hypertension in predicting responsiveness to bevacizumab is controversial. The most comprehensive analysis to date analyzed ϳ5,900 patients across six phase III studies in mCRC and breast, lung, and renal cell cancers [97]. This analysis used patient-specific data, including blood pressure values from each visit.…”

Section: Biomarkersmentioning

confidence: 99%

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Strickler

Hurwitz

2012

The Oncologist

View full text Add to dashboard Cite

Since its approval for the first‐line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab‐based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first‐line setting.

show abstract

Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).

Cited by 39 publications

References 0 publications

Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies

Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies

Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors

Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

Contact Info

Product

Resources

About